Heidelberg, Germany, January 13, 2021 -- Affimed N.V. ("Affimed" or the 
"Company") (Nasdaq: AFMD), a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer, 
today announced the pricing of its previously announced public offering 
of 16,666,667 of its common shares at a public offering price of $6.00 
per common share. In addition, Affimed has granted the underwriters a 
30-day over-allotment option to purchase up to 2,500,000 common shares 
at the public offering price less underwriting discounts. After 
deducting the underwriting discounts, the net proceeds of the public 
offering are expected to be approximately $94 million. The offering is 
expected to close on or about January 15, 2021, subject to customary 
closing conditions. 
 
   Jefferies LLC, SVB Leerink LLC and Credit Suisse Securities (USA) LLC 
are acting as joint book-running managers and Laidlaw & Company (UK) 
Ltd. is acting as co-manager. A shelf registration statement relating to 
these securities filed with the Securities and Exchange Commission (the 
"SEC") was declared effective by the SEC on December 30, 2020. The 
offering will be made only by means of a prospectus and prospectus 
supplement. A preliminary prospectus supplement and accompanying 
prospectus related to the offering have been filed with the SEC and are 
available at the SEC's website located at 
https://www.globenewswire.com/Tracker?data=hJQeNiJ5CL-_NMt9sXP3L_5I5D-_A0ba9eQyKzboL3rJz_PpchpTv-wkfF8NWJ6x6fEJ1DLGwi_hW6xSSK8TvQ== 
www.sec.gov. A final prospectus supplement and accompanying prospectus 
will be filed with the SEC. Copies of the preliminary prospectus 
supplement and accompanying prospectus related to the offering may be 
obtained by contacting Jefferies LLC, Attention: Equity Syndicate 
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 
10022, or by telephone at (877) 821-7388 or by email at 
https://www.globenewswire.com/Tracker?data=eO2mu1zoOd9Iw21YomS0LEK29Y5QvMdBmmuVi2Pgeds5hDON4ljxoQJzgMA82rzgpNDOXoSxGZxFfAOj9-niWO2U4iD39V6ZFTJywR4jJbFpjqcUiM5tb8wbuUUTSBFRlX6iT6uXKlv3OhQbLIER2w== 
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention: 
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, 
by telephone at (800) 808-7525 ext. 6132, or by email at 
https://www.globenewswire.com/Tracker?data=S2WvQ5g0VZ2zezocVXgnWSTTBZ-Y0b5eCJpSUOaL5fMdoKS097Pjhfq1ZGWmXmfyVnH5X5i5btHFY5LpFzGdLZ8aY4i3vJxkdjUJDlbxQNE= 
syndicate@svbleerink.com, or Credit Suisse Securities (USA) LLC, 
Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, 
NC 27560, by telephone at (800) 221-1037, or by email at 
https://www.globenewswire.com/Tracker?data=ivHQaQJiM7sMbXCltYHfUPfWpYa4wrxKCd6_EtAudaNzaVrkNhaQOJFn8sWqDNmHRXTG3haTnvk0sv_dGpPlJn_Jzmrc96LECOGQYLYAxMGtK2uHq_a8rKXYNWSEbM7k 
usa.prospectus@credit-suisse.com. 
 
   This press release shall not constitute an offer to sell or a 
solicitation of an offer to buy, nor shall there be any sale of, these 
securities in any state or jurisdiction in which such offer, 
solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of any such state or 
jurisdiction. 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer. 
Affimed's fit-for-purpose ROCK(R) platform allows innate cell engagers 
to be designed for specific patient populations. The company is 
developing single and combination therapies to treat hematologic and 
solid tumors. The company is currently enrolling patients into a 
registration-directed study of AFM13 for CD30-positive 
relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a 
dose escalation/expansion study of AFM24 for the treatment of advanced 
EGFR-expressing solid tumors. 
 
   Forward-looking Statements 
 
   This press release contains statements that constitute "forward-looking 
statements," including with respect to the proposed offering of common 
shares and the anticipated use of the net proceeds. No assurance can be 
given that the offering discussed above will be completed on the terms 
described, or at all, or that the net proceeds of the offering will be 
used as indicated. Forward-looking statements are subject to numerous 
conditions, many of which are beyond the control of the company, 
including those set forth in the Risk Factors section of the company's 
registration statement and preliminary prospectus for the company's 
offering filed with the Securities and Exchange Commission ("SEC"). 
Copies are available on the SEC's website, 
https://www.globenewswire.com/Tracker?data=hJQeNiJ5CL-_NMt9sXP3L5nuOIqGAuTmsa7oMlEUDwUNkVsPKoq-qo_d_rT-EXQN9G78ylQN-ZUJvkcWzg9g0A== 
www.sec.gov. The company undertakes no obligation to update these 
statements for revisions or changes after the date of this release, 
except as required by law. 
 
   Affimed Investor and Media Contact: 
 
   Alexander Fudukidis, Head of Investor Relations 
 
   E-Mail: 
https://www.globenewswire.com/Tracker?data=DfqeXUjlESIjf2Yme_NcxXB6cNCXL0oMMLr3AmQKNXSNgDppus7SK6r0Ct0it2-dr1wjugO95PcCkMnOscnyQsVy3ik8eWig-Jtoth41DmA= 
a.fudukidis@affimed.com, IR@affimed.com 
 
   Tel.: +1 (917) 436-8102

(END) Dow Jones Newswires

January 13, 2021 06:15 ET (11:15 GMT)